Pioneering novel first-in-class oral small molecule drugs featuring MEK/PI3K/mTOR multi-kinase targeting with improved bioavailability and reduced toxicity
Small Molecular Inhibitors The design of small-molecule targeted therapies over the last few decades have achieved inhibition of specific molecules or pathways involved in cancer growth and progression, offering enhanced efficacy and reduced side effects compared to traditional chemotherapy.
Current Challenges While targeted therapies are designed to be less toxic and more selective, targeting of a single cancer signaling node allows for escape mechanisms which tend to lead to observed low response rates, treatment resistance and often undesirable side effects.
Lympharma® Technology The Company has developed patented, multitargeted small molecule drugs which achieve reduced toxicity profiles through intrinsic intestinal lymphatic absorption (‘lymphatropic’) while providing efficacious and durable treatment profiles. Our clinical candidate is LP-182, a multi-targeted kinase inhibitor of MEK, PI3K and mTOR. Orally delivered, it is lymphatically absorbed which provides for reduced systemic toxicity and improved response.
Lympharma Value Proposition A Phase I clinical trial will be undertaken to demonstrate the effectiveness of LP-182 for the treatment of myeloproliferative neoplasms (Myelofibrosis), a cancer which has a 2032 estimated market size of $1.14 billion.